Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma issues $111,111 convertible note to ONE44 Capital LLC

Propanc Biopharma, Inc.

Principal $111,111; net proceeds $100,000 after $11,111 original issue discount.
Interest 10% per annum, payable in common stock; maturity Feb 14, 2024.
Conversion price at 60% of lowest trading price over prior 10 days (50% if DTC chill).
Prepayment allowed within 180 days with premiums of 120%-135% of face amount.
Proceeds used for general working capital; note issued under Section 4(a)(2) exemption.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $111,111 with ONE44 Capital LLC at 10% per annum maturing February 14, 2024.

Instrument: convertible notes
Principal: aggregate principal amount of $111,111
Counterparty: ONE44 Capital LLC
Rate: 10% per annum
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Propanc Biopharma, Inc. entered into Purchase Agreement with ONE44 Capital LLC valued at aggregate principal amount of $111,111 (effective 2023-02-14).

Action: entry
Agreement: equity purchase
Counterparty: ONE44 Capital LLC
Value: aggregate principal amount of $111,111
Effective: 2023-02-14

Exact text from the filing

On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-005702

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.